10-Q: Cosmos Health Reports Mixed Q2, Secures $300M Financing

Cosmos Health Inc. reported increased revenue and gross profit for Q2 2025, alongside a reduced net loss, but acknowledged persistent substantial doubt about its ability to continue as a going concern despite securing a new $300 million convertible note facility.

Summary

• Revenue for the three months ended June 30, 2025, increased by 11.7% to $14,745,702, compared to $13,206,717 in the prior year.
• Revenue for the six months ended June 30, 2025, increased by 2.4% to $28,458,230, compared to $27,791,190 in the prior year.
• Gross profit for the three months ended June 30, 2025, rose by 51.7% to $1,163,814, compared to $767,248 in the prior year, driven by a shift to higher-margin products.
• Gross profit for the six months ended June 30, 2025, increased by 52.7% to $3,213,613, compared to $2,100,874 in the prior year.
• Net loss for the three months ended June 30, 2025, increased by 9.2% to $(2,828,068), compared to $(2,590,711) in the prior year, primarily due to non-cash interest expense and fair value changes of convertible notes.
• Net loss for the six months ended June 30, 2025, decreased by 18.2% to $(3,646,165), compared to $(4,457,401) in the prior year.
• Net cash used in operating activities for the six months ended June 30, 2025, significantly decreased to $(1,396,236), from $(4,622,989) in the prior year.
• Cash and cash equivalents increased to $655,503 as of June 30, 2025, from $315,105 as of December 31, 2024.
• Negative working capital worsened to $(604,249) as of June 30, 2025, from $(296,193) as of December 31, 2024.
• The company entered into a Securities Purchase Agreement on August 5, 2025, for up to $300 million of senior secured convertible promissory notes, with an initial $8 million closing on August 6, 2025.
• Material weaknesses in internal controls over financial reporting were identified, including a lack of proper segregation of duties and insufficient IT General Controls, with remediation planned by December 31, 2025.

Sentiment

Score: 4

Explanation: While revenue and gross profit showed positive trends and a significant financing facility was secured, the company continues to report net losses, has worsening negative working capital, and explicitly states 'substantial doubt' about its ability to continue as a going concern. The reliance on external financing and ongoing operational challenges temper optimism.

Positives

• Revenue increased by 11.7% for the three months and 2.4% for the six months ended June 30, 2025, indicating continued top-line growth.
• Gross profit significantly improved by 51.7% for the three months and 52.7% for the six months ended June 30, 2025, driven by a favorable shift towards higher-margin nutraceuticals and contract manufacturing.
• Net loss decreased by 18.2% for the six months ended June 30, 2025, reflecting improved operational efficiency and gross profit.
• Net cash used in operating activities decreased substantially from $(4,622,989) in H1 2024 to $(1,396,236) in H1 2025, indicating reduced cash burn from core operations.
• Secured a significant financing facility of up to $300 million in senior secured convertible promissory notes, with an initial $8 million closing, which is expected to significantly improve liquidity.
• Strategic focus on expanding high-margin segments like nutraceuticals (Sky Premium Life, Mediterranation) and pharmaceutical manufacturing (CANA S.A.) is yielding positive results.
• Expansion into new geographical regions, such as the exclusive distribution of Sky Premium Life products in the UAE, with significant purchase orders already received.
• Investment in R&D, including the Cloudscreen AI platform for drug repurposing and oncology research, positions the company for future innovation.

Negatives

• The company continues to incur net losses, with a net loss of $(2,828,068) for the three months and $(3,646,165) for the six months ended June 30, 2025.
• Negative working capital worsened to $(604,249) as of June 30, 2025, from $(296,193) as of December 31, 2024, indicating ongoing short-term liquidity challenges.
• Accumulated deficit increased to $(117,668,440) as of June 30, 2025, highlighting historical losses.
• Substantial doubt about the company's ability to continue as a going concern persists, despite recent financing efforts.
• Operating expenses increased by 16.5% for the three months and 3.9% for the six months ended June 30, 2025, primarily due to higher salaries and professional service fees.
• Interest expense increased by 13.6% for the three months and 12.7% for the six months ended June 30, 2025, due to new financing arrangements.
• Significant related party transactions, including substantial prepaid balances to Doc Pharma S.A. and accounts receivable from Maria Kozari's pharmacy with a high allowance for doubtful accounts, raise concerns about financial transparency and collectability.
• Material weaknesses in internal controls over financial reporting were identified, specifically a lack of proper segregation of duties and inadequate IT General Controls, which could impact financial reporting reliability.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months, as revenues remain insufficient to fund operating expenses and meet debt obligations.
• The company remains dependent on external financing sources to sustain operations and fund growth initiatives, with no assurance of successful execution of plans or obtaining necessary funding.
• Supply chain disruptions are a growing concern for the European pharmaceutical industry, potentially impacting the timely supply of materials, services, and products.
• Volatility in the availability and cost of materials or services, including rising prices due to inflation, could adversely affect manufacturing operations and profitability.
• Difficulties or delays in obtaining required import or export approvals, or shipment delays due to transportation interruptions, could impact product delivery.
• Information technology or infrastructure failures, including those of third-party suppliers, pose operational risks.
• Natural disasters or other events beyond the company's control (e.g., geopolitical turmoil, health epidemics) could adversely affect operations.
• Hikes in medicine prices and cuts in healthcare spending, particularly in EU member states like Greece, could impact market conditions and profitability.
• Ongoing legal proceedings, including a tax audit-related fine, criminal cases, and pending lawsuits against hospitals, could result in financial liabilities or operational distractions.
• The Montreal building acquisition closing date was extended to December 31, 2025, indicating potential delays in strategic asset utilization.
• The CMO agreement with Doc Pharma states that Doc Pharma is not responsible for potential delays concerning the import of raw materials, shifting this risk to the company.
• Material weaknesses in internal controls over financial reporting, such as lack of segregation of duties and inadequate IT General Controls, could lead to financial misstatements or fraud.

Future Outlook

The company plans to expand its portfolio of brand-name and private-label products, launch new distribution channels, and increase sales from recently secured agreements, such as the exclusive distribution of Sky Premium Life products in the UAE. It intends to expand the customer base of Cosmofarm S.A. and strengthen contract manufacturing agreements for CANA S.A. From a financing perspective, the company plans to continue accessing capital markets through equity offerings, expecting to utilize an S-3 registration statement from August 2025 for more efficient capital access. Management is also pursuing amendments to debt facilities to defer principal repayments and exploring additional debt financing opportunities. Strategic plans include active acquisitions, expanding the R&D division for novel nutraceuticals and generics, enhancing business development and marketing, global expansion via various channels, and investing in production capacity and key personnel. The company also aims to accelerate R&D efforts on IP-driven products like CCX0722 (obesity) and CCDL24 (gastrointestinal disorders), and cancer treatments, leveraging its Cloudscreen AI platform. The acquisition of Pharmacy & More is planned for fiscal year 2025, and remediation of internal control weaknesses is targeted for completion by December 31, 2025.

Management Comments

• Management intends to continue accessing capital markets to raise additional funds through equity offerings.
• Beginning in August 2025, the company expects to become eligible to utilize an S3 registration statement to access equity capital more efficiently.
• The availability of proceeds from the $300 million financing facility, primarily intended for digital asset acquisition and working capital, significantly improves liquidity and alleviates substantial doubt regarding the ability to continue as a going concern for at least the next 12 months.
• Management is also considering postponing certain payments to suppliers and other creditors if required.
• Although these actions are intended to address the going concern uncertainty, there can be no assurance that the company will be successful in executing its plans or obtaining the necessary funding. As a result, substantial doubt remains regarding the company's ability to continue as a going concern for a period of 12 months from the date of this filing.
• Our strategic plan, which strikes a balance between growth and sustainability, emphasizes synergies, vertical integration, operational efficiencies, R&D, brand expansion, and the global growth of our distribution network and facilities.
• We are in the process of remediating all material weaknesses present in our internal controls and we plan to have completed the remediation by December 31, 2025.

Industry Context

The company operates within the international healthcare group, specializing in nutraceuticals, pharmaceuticals, and healthcare distribution. The European pharmaceutical industry faces growing concerns over supply chain disruptions and increasing scrutiny on medicine prices, with regulators pushing for competition to drive down costs. The company's strategy of vertical integration, R&D in novel nutraceuticals and generics, and leveraging AI for drug repurposing aligns with industry trends focusing on innovation and efficiency. The global demand for nutraceutical products is increasing, presenting a high-growth opportunity that the company is actively pursuing with its proprietary brands and expanded distribution channels.

Comparison to Industry Standards

• CANA S.A. has earned the trust of industry giants like AstraZeneca, Merck, Unilever, and Procter & Gamble, indicating a strong reputation within the pharmaceutical manufacturing sector.
• The company's manufacturing processes adhere to strict pharmaceutical standards and Good Manufacturing Practice (GMP) protocols as required by the National Organization for Medicines, ensuring high-quality production.
• Subsidiaries are ISO 9001 certified for management systems in pharmaceutical trade and distribution, demonstrating compliance with international quality management standards.
• Distribution facilities are GDP licensed, ensuring efficient and secure medication delivery, which is a standard requirement in the healthcare distribution industry.

Management Changes

Corporate Governance

Legal Proceedings

• A payment request was issued by the Greek court in relation to a fine arising from a tax audit of Cosmofarm for the financial year 2014. The company settled additional taxes and fines of $99,644 but has filed a claim to recover the amount through appeal; the trial remains pending.
• A criminal case involving dishonored checks issued by Cosmofarm's customer, Kafantaris, resulted in the defendant's conviction under Decision No. 1599/2024 on January 26, 2024.
• The company's appeal against Eleutheria Drakopoulou and Decision No. 1389/2021 was partially accepted, and the case was settled by Cosmofarm SA in two equal installments of €35,000 ($37,880 on July 31, 2024, and $37,993 on October 31, 2024).
• Cana Laboratories has two pending lawsuits against Euaggelismos Hospital for unpaid bills totaling €526,436, with one court date scheduled for December 11, 2024, and the other unscheduled. Legal counsel assesses collection as highly probable.
• An unasserted claim exists against Papanikolaou Hospital for €89,300 due to unpaid bills, which will be asserted through a lawsuit. Legal counsel anticipates a probable success and collection.
• A lawsuit filed on April 5, 2018, by a former employee against Cana Laboratories for nullification of termination and compensation was settled on April 28, 2025, for €62,500 ($83,719) in nine scheduled installments.
• A lawsuit has been filed against Cana seeking restitution of a leased property, payment of approximately €13,190 in outstanding rent, and €8,488 in compensation. Monetary claims were settled, but the claim for restitution of the leased property remains pending.
• Cosmofarm SA is initiating legal action to recover approximately €20,301 in unpaid invoices from one customer, with the hearing expected in 2026. Legal counsel anticipates the claim to be upheld.
• Cosmofarm SA is preparing to file two further lawsuits for the recovery of €15,143 and €15,255, respectively, related to unpaid invoices concerning two customers, with hearings expected in 2026 and favorable outcomes anticipated.

Related Party Transactions

• Doc Pharma S.A. (CEO's son is CEO): Prepaid expenses of $4,273,089 as of June 30, 2025, for inventory, licenses, and a royalty agreement. Accounts payable of $498,988. Accounts receivable of $2,606,798, with a $1.6 million allowance for doubtful accounts. Purchases of $658,019 and sales of $263,757 for the six months ended June 30, 2025. Doc Pharma also owes the company $815,706 (current) and $3,204,580 (non-current) from a loan, with no principal or interest received in H1 2025. The company also has a royalty agreement for cancer treatment patents with DocPharma SA.
• Maria Kozari (daughter of Panagiotis Kozaris, Cosmofarm employee): Accounts receivable of $1,347,235 as of June 30, 2025, from Pharmacy & More, with a $909,881 allowance for doubtful accounts. The company plans to acquire Pharmacy & More in fiscal year 2025.
• Panagiotis Kozaris (former General Operational Manager and current employee of Cosmofarm S.A.): Prepaid expenses of $194,215 as of June 30, 2025, for shares to be purchased.
• Basotho Investment Limited (Panagiotis Kozaris is a director): Issued 120,000 shares of common stock for services rendered on November 21, 2023.
• Grigorios Siokas (CEO): Prepaid salaries of $296,947 as of June 30, 2025. Issued 3,096,954 shares of common stock between January 13, 2025, and May 23, 2025, in settlement of $1,434,978 in outstanding obligations (unpaid salaries and performance-related bonuses).
• George Terzis (CFO): Unpaid salaries and bonuses of $228,000 as of June 30, 2025.
• Nikolaos Bardakis (COO): Unpaid salaries and bonuses of $16,588 as of June 30, 2025.
• Dimitrios Goulielmos (former CEO and Director): Notes payable of $12,040 as of June 30, 2025, from a non-interest bearing, no-maturity loan.

Stakeholder Impact

• Shareholders face potential dilution from recent and planned stock issuances (e.g., to CEO, consultants, convertible noteholders) and future equity raises.
• Shareholders are exposed to significant uncertainty regarding the company's ability to continue as a going concern, which could impact share value.
• Employees, particularly management and scientific personnel at Cana, have seen additions, and stock-based compensation is a component of remuneration for officers, directors, and key employees.
• Customers may benefit from an expanded product portfolio and distribution network, but potential supply chain delays could impact product availability.
• Suppliers and creditors face the risk of postponed payments, as management is considering this option if required, and the company has significant outstanding debt and related-party payables.
• Convertible noteholders have secured notes and the potential for conversion into common stock, which could offer upside but also exposes them to equity risk.

Next Steps

• Expand the portfolio of brand-name and private-label products.
• Launch new distribution channels and increase sales from recently secured agreements, such as the exclusive distribution of Sky Premium Life products in the UAE.
• Expand the customer base of Cosmofarm S.A. to substantially increase its wholesale revenue stream.
• Strengthen existing and secure new contract manufacturing agreements for CANA S.A.
• Access capital markets to raise additional funds through equity offerings, potentially utilizing an S-3 registration statement from August 2025.
• Pursue amendments to certain debt facilities to defer principal repayments and explore additional debt financing opportunities.
• Consider postponing certain payments to suppliers and other creditors if required.
• Continue active ongoing acquisitions and joint ventures to enhance the distribution network.
• Expand the R&D division to develop new patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products.
• Enhance business development and marketing efforts, pursue global expansion via prominent retailers, pharmacies, and e-commerce platforms.
• Recapture lost markets, such as the infant and baby care categories.
• Invest in the expansion of production capacity and global network of facilities to boost sales of brands and engage in contract manufacturing.
• Strategically invest in key personnel, including seasoned export managers and highly skilled scientists.
• Accelerate R&D efforts on IP-driven products such as the CCX0722 obesity and weight management pill, CCDL24 for gastrointestinal disorders, and cancer treatments.
• Utilize the recently acquired Cloudscreen AI-driven drug repurposing platform.
• Acquire Pharmacy & More within fiscal year 2025, intending to offset the outstanding receivable balance with the purchase price and establish it as the first shop-in-shop for Sky Premium Life products.
• Remediate material weaknesses in internal controls over financial reporting by December 31, 2025.

Key Dates

Recommendation

While Cosmos Health Inc. demonstrated positive trends in revenue growth and gross profit, and successfully secured a substantial $300 million financing facility, the persistent 'substantial doubt' about its ability to continue as a going concern signals significant underlying financial instability. The company's worsening negative working capital, ongoing net losses, and identified material weaknesses in internal controls present considerable risks. The strategic initiatives and R&D investments offer long-term potential, but the immediate financial health remains precarious. A 'Hold' recommendation reflects the balance between these positive developments and the severe, acknowledged risks, suggesting investors monitor the execution of the strategic plan and the remediation of financial weaknesses before making further commitments.

Keywords

Healthcare, Pharmaceuticals, Nutraceuticals, SEC Filing, 10-Q, Financial Results, Going Concern, Convertible Notes, AI Platform, Drug Repurposing, Contract Manufacturing, Wholesale Distribution, Sky Premium Life, CANA S.A., Cosmofarm S.A., Greece, United Kingdom, UAE, Nasdaq, Corporate Governance, Internal Controls, Related Party Transactions, Equity Financing, Debt Financing, Ethereum